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ABSTRACT   Wnt signaling is a ubiquitous system for intercellu-
lar communication, with multiple functions during development 
and in homeostasis of the body. It comprises several ligands, recep-
tors, and inhibitors. Some molecules, such as sclerostin, appear 
to have bone-specific functions, and can be targeted by potential 
drugs. Now, ongoing clinical trials are testing these drugs as treat-
ments for osteoporosis. Animal studies have also suggested that 
these drugs can accelerate fracture healing and implant fixation. 
This brief overview focuses on currently available information on 
the effects of manipulations of Wnt signaling on bone healing. 
 
Abbreviations
BMP  Bone morphogenic protein
Dkk Dickkopf
Frzb  Frizzled-related protein
Fz Frizzled
GSK3ß  Glycogen synthase kinase-3 ß
Lef  Lymphoid enhancer binding factor
LRP4, -5, -6  Low-density lipoprotein receptor-related proteins 4, 5, and 6
OPG Osteoprotegerin
PTH  Parathyroid hormone
RANKL  Receptor activator of nuclear factor kappa B ligand
sFrp  Secreted Frizzled-related protein
Tcf  T-cell factor
TNF-a  Tumor necrosis factor a
Wif1,2  Wnt inhibitory factor
Wise  Wnt modulator in surface ectoderm
Wnt2, -3a, -4, -5a, -5b, -10 
  Wnt ligand 2, 3a, 4, 5a, 5b, and 10
Wnts  Wnt ligands
 
What is Wnt signaling? 
When the orthopedics community learned about bone mor-
phogenetic proteins (BMPs) in the 1990s, the expectations 
about new therapeutic possibilities may have been unrealistic, 
but after a long delay some of these expectations have actu-
ally been met (Agarwal et al. 2009). The BMPs are part of a 
ubiquitous signaling system with some specific functions in 
bone. They are not alone, however: another signaling system 
has recently turned out to be important for bone homeosta-
sis and regeneration, with perhaps even greater potential for 
therapeutic application—namely Wnt signaling. Drugs that 
interfere with this pathway are now close to clinical testing for 
acceleration of fracture healing. Similarly to PTH, these drugs 
might become useful tools for the orthopedic surgeon. 
This paper is not a formal literature review, but is intended 
to give an overview of studies of Wnt signaling that are of 
relevance to the field of orthopedics. We searched Pubmed and 
clinicaltrials.gov with the terms “Wnt bone formation”, “Wnt 
bone fracture”, “Wnt osteoarthritis”, and “Wnt bone implant”. 
Review articles and original work were included. We excluded 
studies that focus on cancer and those with only in vitro data, 
and tried to make a synthesis of the 174 articles that remained. 
Wnts are secreted signaling proteins that increase 
intracellular ß-catenin
Natural mutations in humans gave the first indication of the 
importance of Wnt signaling in bone formation. The affected 
subjects had a several-fold increase in bone mass, with few 
other changes. Study of these mutations in transgenic animals 
suggested a therapeutic potential for drugs that interfere with 
Wnt signaling to increase bone mass. 
Wnt ligands (Wnts) are a group of secreted proteins that are 
important for embryonic development, as well as cell prolifer-
ation and differentiation in the adult (Logan and Nusse 2004).   
The complete signaling process has been reviewed in detail 
by others (Logan and Nusse 2004, MacDonald et al. 2009, 126  Acta Orthopaedica 2011; 82 (2): 125–130
Macsai et al. 2008), and we will only describe it briefly before 
discussing its possible importance for orthopedics. Currently, 
19 Wnt homologs have been described in humans, with a wide 
range of functions and expression patterns. The name Wnt is 
derived from a combination of Wg (Wingless gene in Dro-
sophila) and Int-1 (gene from the integration site of mouse 
mammary tumor virus). It was coined when these two genes 
were shown to be homologous (Rijsewijk et al. 1987). 
Wnts interact with receptors that activate several sets of 
intracellular signaling pathways. These pathways can be sub-
divided into canonical Wnt signaling and non-canonical Wnt 
signaling. Canonical Wnt signaling is the most studied, and 
this overview will center on this pathway, since it appears 
to be the most important in bone. The hallmark of canonical 
Wnt signaling is the stabilization of ß-catenin in the cytosol, 
which enables it to translocate to the nucleus and regulate 
gene expression (Figure 1). In contrast, the non-canonical 
pathways function without ß-catenin. Initially, Wnts bind to 
a specific receptor belonging to the Frizzled (Fz) group (there 
are at least 10 of them). A receptor complex is then formed 
with low-density lipoprotein receptor-related proteins (LRPs) 
4, 5, and 6. This event prevents an intracellular protein com-
plex consisting of Axin, GSK3ß, and APC from tagging 
ß-catenin for degradation. As a result, ß-catenin accumulates 
in the cytosol and can translocate into the nucleus, where it 
interacts with members of the Tcf/Lef class of DNA binding 
proteins and transcriptions factors. Precise regulation of this 
system is vital, especially in embryonic development. Correct 
formation and function of the nervous system, brain, heart, 
and kidneys is also dependent on this system (Macsai 2008). 
Wnt signaling is also implicated in cancer, by increasing cell 
proliferation (MacDonald 2009). Far from being isolated, Wnt 
signaling is prone to crosstalk with other pathways, notably 
those connected to PTH (Guo et al. 2010) and BMPs (Itasaki 
and Hoppler 2010). 
Wnt signaling is regulated by soluble inhibitors 
There are several feedback loops, with both secreted and 
intracellular inhibitors, which modify Wnt signaling (Figure 
1). These secreted inhibitors include sclerostin (the product 
of the SOST gene), the Dickkopfs (Dkks), secreted Frizzled-
related proteins (sFrps), Frizzled-related protein (Frzb), Wnt1-
induced secreted protein (WISE), Wnt inhibitory factor-1 and 
-2 (Wif-1, Wif-2) and Chibby (Galli et al. 2010). The secreted 
inhibitors are particularly interesting, as they can be targeted 
by therapeutic antibodies, some of which appear to be effica-
cious and safe in clinical settings. 
Wnt signaling in development
Wnt signaling is required to establish the head–to-tail 
axis
In all animals studied, Wnt signaling is crucial for embryonic 
development (van Amerongen and Nusse 2009). It is required 
for processes that regulate the establishment of head–to-tail 
axis, limb polarity, neural crest differentiation, kidney mor-
phogenesis, and sex determination. Disruption of this pathway 
can lead to major developmental disabilities. It is not only the 
Wnt ligands that need to be present; Wnt inhibitors are equally 
important. For example, embryos lacking Dickkopf-1 (Dkk1) 
do not develop heads (hence the name Dickkopf) (Glinka et 
al. 1998).  In contrast, when the inhibitors sclerostin or sFrp1 
are absent in vivo, the only tissue that appears to be affected 
is the skeleton ( Li 2008 et al., Gaur et al. 2009). The recep-
tors LRP5 and LRP6 have received much attention, since they 
seem to be partially redundant but still vital to development. 
In vivo experiments have shown LRP6-deficency to be fatal, 
while animals with a deficiency in LRP4 and LRP5 are viable 
(MacDonald et al. 2009). These developmental studies have 
been helpful in elucidating the important role of Wnt signaling 
in cell proliferation and differentiation—not just in bone, but 
also in other tissues.  
Figure 1. Canonical Wnt signaling. In the active state, Wnt ligands 
(Wnt) form a complex with the receptors low-density lipoprotein recep-
tor-related protein 5 or 6 (LRP5/6) and Frizzled (Fz). Disheveled (Dsh) 
is then able to bind to Fz. Dsh forms a complex with glycogen synthase 
kinase 3ß (GSK3ß), Axin, and adenomatous polyposis coli (APC). This 
protects ß-catenin from proteasomal degradation so that ß-Catenin 
can accumulate in the cytosol and translocate to the nucleus. In the 
nucleus it interacts with the T-cell factor/lymphoid enhancer factor 
(TCF/LEF) family of transcription factors, leading to gene transcription. 
Inhibitors of this system prevent the formation of the Wnt-Fz-LRP5/6 
complex, inactivating Wnt signaling. This leads to GSK3ß-mediated 
phosphorylation of ß-catenin, causing it to be degraded. A variety 
of extracellular inhibitors serve as inactivators. Dickkopf (Dkk) and 
sclerostin (Sost) bind to LRP5/6, preventing Wnt binding. Secreted 
Frizzled-related protein (sFrp) has similarities with Frizzled, and can 
bind either to the Wnt ligand or to the Fz receptor itself. Frizzled-related 
protein (Frzb) acts as a decoy receptor for Wnt ligands. Wnt-inhibitory 
factor (Wif) also binds directly to the Wnt ligand (Komatsu and Warden 
2010, MacDonald 2009, Macsai 2008).Acta Orthopaedica 2011; 82 (2): 125–130  127
Wnt signaling in bone
Wnt signaling is important for bone maintenance and 
repair 
ß-catenin is needed both to promote early osteoblast prolif-
eration and differentiation (Galli et al. 2010) and to suppress 
osteoclasts. ß-catenin accumulation favors mesenchymal stem 
cell commitment for an osteogenic fate, away from the adipo-
genic or chondrogenic lineage (Case and Rubin 2010). Pre-
cise regulation of ß-catenin via Wnt signaling is needed for a 
proper healing response (Chen et al. 2007, Kim et al. 2007), 
and mutations in parts of this system either lead to excessive 
bone growth or to bone resorption. For example, loss-of-func-
tion mutations in LRP5 lead to the human osteoporosis pseu-
doglioma syndrome, with low bone mass (Gong et al. 2001), 
whereas gain of function leads to high bone mass (Boyden 
et al. 2002, Little et al. 2002, Semenov and He 2006). Con-
sequently, loss-of-function mutations affecting the inhibitor 
sclerostin (van Bezooijen et al. 2005 , Semenov and He 2006) 
give rise to a very high bone mass phenotype in humans, char-
acterized by generalized cortical hyperostosis—van Buchem’s 
disease (Balemans et al. 2002). 
Wnt signaling is involved in the response of bone to 
mechanical loading 
Sclerostin also plays an important role in how bone responds 
to mechanical loading (Lin et al. 2009, Robling et al. 2008) 
(Figure 2). There are also some indications that Dkk1 is 
involved, although to a lesser degree than sclerostin, in the 
response of bone to mechanical loading (Robling et al. 2008). 
Furthermore, deficiency of one or both of the genes for the 
inhibitor Dkk1 leads to increased bone mass and stronger 
bone (MacDonald et al. 2007, McDonald et al. 2010, Morvan 
et al. 2006). Lithium is an inhibitor of GSK3ß, which is a pro-
tein in the intracellular cascade that phosphorylates ß-catenin. 
Lithium thus increases ß-catenin levels, which promotes bone 
formation and increases bone mass in mice (Clement-Lacroix 
et al. 2005). There are some indications that it may also have 
these effects in the clinic (Vestergaard et al. 2005, Zamani et 
al. 2009). 
Some common polymorphisms of the Wnt receptor LRP5 
gene are associated with osteoporotic fractures, and polymor-
phisms of LRP6 are associated with low bone mineral density, 
thus explaining some of the influence of heredity on osteopo-
rosis (Riancho et al. 2010). These mutations point to the possi-
bility of modulating Wnt signaling for orthopedic purposes, as 
few organs except bone appear to be affected. Moreover, these 
effects arise after lifelong exposure, suggesting that limited 
short-term use of agents that modulate the pathway could be 
safe and suitable for clinical practice. 
Wnt signaling in fracture healing
Increased Wnt signaling improves bone healing 
ß-Catenin is important for bone healing (Chen et al. 2007, 
Kim et al. 2007) and consequently, modulation of Wnt 
signaling has been shown to influence fracture healing. 
The Table is a summary of the modulation methods used 
Figure 2. Wnt signaling in mechanotransduction: 1. The Wnt inhibitor 
sclerostin is secreted from osteocytes and blocks stimulation of lining 
cells. 2. Deformation due to mechanical loading is perceived by osteo-
cytes, which reduce sclerostin secretion, thus permitting surface cells 
to be activated by Wnt ligands. 3. Bone apposition reduces deformation 
and sclerostin secretion is increased again.
Changes in Wnt signaling and fracture healing 
Component  Role  Administration  Animal  Fracture model  Main finding  Reference
Wnt3a  Ligand  Liposomal, local  Mouse  Proximal tibia  Enhanced bone regeneration  Minear et al. 2010
          by Wnt3a administration
Sclerostin  Inhibitor  Antibody, systemic  Rat  Proximal tibia  Increased bone formation in both  Agholme et al. 2010  
          traumatized and untraumatized bone
Sclerostin  Inhibitor  Antibody, systemic  Rat / Monkey  Femur shaft /  Reduced cartilage formation and  Ominsky et al. 2010
        fibular osteotomy  improved fracture healing       
       otomy 
Dkk1  Inhibitor  Antibody, systemic  LRP5-/- Mouse  Femur shaft  Improved fracture healing  Komatsu et al. 2010 
Dkk1  Inhibitor  Antibody, systemic  Rat  Proximal tibia  Increased bone formation and  Agholme et al. 2011
          improved implant fixation and  
          fracture repair
sFrp1  Inhibitor  Genetic modification  sFrp1-/- Mouse  Tibia shaft  Faster and better fracture repair  Gaur et al. 2009
LiCl  Inhibitor  Oral  Mouse  Tibia shaft  Treatment improves fracture  Chen et al. 2007   
          healing if initiated after the
          fracture has occurred128  Acta Orthopaedica 2011; 82 (2): 125–130
to enhance healing. In an endochondral setting, ß-catenin 
appears to have different effects at different stages of bone 
repair. Early in the process, it controls the relation between 
the numbers of osteoblasts and chondrocytes that arise from 
the pluripotent mesenchymal cells. Thus, either too much 
or too little ß-catenin can be detrimental to bone healing 
at this stage. Later on, ß-catenin promotes the differentia-
tion of osteoblasts and enhances their production of bone 
matrix, so that too little ß-catenin at this stage impairs heal-
ing whereas raised ß-catenin levels improve healing (Chen 
et al. 2007). Gene expression studies in diaphyseal fractures 
in rats have shown increased ß-catenin expression on day 3 
after fracture, peaking at 10 days and leveling out at 21 days, 
but remaining up-regulated thereafter (Hadjiargyrou et al. 
2002, Zhong et al. 2006). Another study in mice showed that 
the ligands Wnt4, 5a, 5b, 10b, and also Dkk1 and sclerostin 
were upregulated in a similar pattern, with a peak around 
day 10 but quite low expression during the first days. On the 
other hand, the receptors LRP5 and LRP6 were upregulated 
from day 1 (Kakar et al. 2007). Moreover, in the same study, 
PTH treatment increased the expression of these Wnt fac-
tors, indicating that there was interaction between PTH and 
Wnt signaling (Kakar et al. 2007). This connection may be 
important, because intermittent PTH injections are the only 
systemic treatment that has so far been shown to improve 
fracture healing clinically (Aspenberg et al. 2010, Aspenberg 
and Johansson 2010). 
Wnt signaling stimulates direct bone formation 
Wnt signaling is also important for metaplastic (intramem-
branous) bone formation, as has been shown in bone healing 
models without cartilage formation. The healing of drill holes 
in the mouse proximal tibia is dependent on Wnt-mediated 
ß-catenin signaling (Kim et al. 2007). Gene expression during 
intramembranous bone formation caused by marrow ablation 
has been studied in rats at several time points after the injury. 
Genes involved in Wnt signaling were found to be upregu-
lated, with a peak after 10 days and then leveling out. Ligands 
were upregulated (Wnt2, -5a, and -5b) as well as receptors 
(LRP4 and -6, and several of the Fz receptors) and inhibitors 
(sFrps, Wise, and Frzb) (Wise et al. 2010). 
Blocking of either of the Wnt inhibitors sclerostin and 
Dkk-1 alleviates osteoporosis and stimulates fracture 
healing
There is firm evidence for the importance of Wnt signaling 
in bone healing. Thus, there have been efforts to influence 
healing by blocking the inhibitors of the Wnt pathway. Two 
inhibitors in particular have been studied more extensively, 
namely sclerostin and Dkk1. Both sclerostin and Dkk1 inhibit 
only canonical Wnt signaling and their main effects appear to 
be on the skeleton. Antibodies that block sclerostin are there-
fore being evaluated for osteoporosis treatment. They increase 
bone mass and counter the effects of ovariectomy in both 
rodents and monkeys (Li et al. 2009, 2010, Ominsky et al. 
2010). A phase-2 clinical trial has indicated that they are safe 
and lead to increasing bone density in osteoporosis (Padhi et 
al. 2011). In addition, clinical trials regarding fracture healing 
are under way. 
Slerostin-blocking antibodies improve screw fixation and 
increase intramembranous bone formation in the proximal 
tibia of rats (Agholme et al. 2010), and also in midshaft frac-
tures in rats (Ominsky et al. 2010). These antibodies also 
counter the effects of mechanical load deprivation, highlight-
ing the importance of sclerostin as a mechanotransducer in 
bone (Tian et al. 2010). In a similar way, in mice, antibodies 
to Dkk1 increase bone volume and density (Glantschnig et al. 
2010), increase callus size and bone formation (Komatsu et 
al. 2010), and protect against inflammatory bone loss (Diarra 
et al. 2007). Furthermore, data from our laboratory suggest 
that inhibition of Dkk1 with antibodies has effects on implant 
fixation and bone regeneration that are similar to those of 
anti-sclerostin antibodies (Agholme et al. 2011). Both types 
of antibodies attenuated bone loss in the proximal rat tibia 
after mechanical unloading, However, neither of them alone 
was able to completely preserve bone mass, suggesting redun-
dancy in this signaling system (own unpublished data).
There may be more ways to increase Wnt signaling
Knockout mice lacking sFrp1 have higher bone mass and 
diaphyseal fractures heal more quickly. The faster healing, 
with no loss of bone quality, is due to increased metaplastic, 
direct bone formation and less cartilaginous callus (Gaur et al. 
2009). Increased osteoclast activity was also noted, but this 
could be attributed to the need for more woven bone to be 
remodeled. 
The intracellular pathway of canonical Wnt signaling, i.e. 
the regulation of ß-catenin levels, appears to also disclose 
targets for drug treatment. Thus, inhibition of GSK3ß using 
lithium has a positive effect on bone formation if administered 
after the initiation of trauma (Chen et al. 2007). However, 
unpublished data from our laboratory, using oral administra-
tion of lithium, have not shown any substantial effects on bone 
healing like the ones experienced with antibodies to scleros-
tin or Dkk1. Other drugs can also modify GSK3ß function 
and promote the differentiation of osteogenic progenitors 
(Gambardella et al. 2010). However, GSK3ß appears to have 
many important functions apart from regulation of bone, and 
is also regulated by systems other than Wnt signaling. Thus, 
drugs that target ß-catenin directly may have too many adverse 
effects. 
Another way of influencing Wnt signaling is to supply more 
Wnt ligand. Wnt3a, applied locally to a drill hole in the proxi-
mal tibia of mice, induced upregulation of ß-catenin expres-
sion and accelerated bone healing (Minear et al. 2010). Local 
administration of Wnt3a increased peri-implant bone forma-
tion around stainless-steel implants in mice. This transient 
delivery of Wnt ligand increased the differentiation of peri-Acta Orthopaedica 2011; 82 (2): 125–130  129
implant cells towards an osteoblastic phenotype (Popelut et 
al. 2010). The importance of this for implant osseointegration 
is also supported by another study, in which both Dkk1 and 
Dkk2 were found to influence early osteoblast differentiation 
on titanium surfaces in vitro. The expression of these genes 
was also dependent on implant surface specifications (Oliva-
res-Navarrete et al. 2010). In summary, increased Wnt signal-
ing seems to enhance bone formation, and this can be achieved 
either by administration of more Wnt ligand or by removal of 
an inhibitor.
Wnt signaling and joint disease
Dkk1 is involved in joint destruction and osteophyte 
formation 
Dkk1 appears to be a key regulator of pathological bone 
remodeling in joint disease. Changes in Dkk1 expression 
may be responsible for many of the differences in radio-
logical appearance between osteoarthritis and rheumatoid 
arthritis. Overexpression of TNF-a in transgenic mice leads 
to synovitis and joint destruction similar to that in rheuma-
toid arthritis. TNF-a also increases Dkk1 expression in the 
inflamed synovium, leading to inability to repair the arthritic 
erosions. When Dkk1 was blocked with an antibody, no joint 
destruction developed, in spite of the TNF-a. Instead, osteo-
phytes formed, making the joint appear osteoarthritic (Diarra 
et al. 2007). Dkk1 was induced by TNF-a but did not par-
ticipate in inflammation: it had its sole effect on bone. Dkk1 
can also increase the expression of sclerostin, thus further 
exacerbating the inability to replace bone that has been lost 
due to inflammation (Heiland et al. 2010). In contrast to the 
upregulation with inflammation induced by TNF-a, Dkk1 is 
downregulated in ankylosing spondylitis and osteoarthritis. 
This leads to increased bone formation and the formation of 
osteophytes (Diarra et al. 2007). Downregulation of Dkk1 is 
possibly responsible for the ankylosis in spondylitis. There are 
also complex cross reactions with the regulation of osteoclast 
activity via the OPG /RANKL system.
What’s in it for the orthopedic surgeon?
Wnt signal modulators may become orthopedic tools 
We believe that in the future, orthopedic surgeons and rheu-
matologists will use drugs that the modulate the Wnt signaling 
system. Especially in fracture treatment, the use of inhibitory 
antibodies is likely to be safe and cost-effective—considering 
the limited treatment time. Because some of the Wnt inhibitors 
are expressed and secreted only in bone, antibodies to them 
will have few side effects outside the skeleton. The orthope-
dic toolbox will contain several drugs with some effects on 
bone healing, such as BMPs, PTH, and Wnt modulators. How-
ever, their effects will be different. It is now clear that BMP-2 
performs better than cancellous autografts for spine fusion 
(Agarwal et al. 2009). BMPs are known for their ability to 
induce bone formation from unconditioned cells, mainly via 
the endochondral pathway. This is also the cause of some of 
its adverse effects. In contrast, sclerostin antibodies can only 
function if sclerostin-producing bone cells are already at hand, 
and will then favor metaplastic bone formation. PTH appears 
to lie somewhere between BMPs and sclerostin antibodies, 
in that it mainly stimulates cells that already belong to the 
osteoblastic lineage, but it does not require the mature cells 
that produce sclerostin. However, its efficacy may be limited 
because of dosage problems. In contrast to BMPs, PTH and 
sclerostin antibodies must be given systemically and do not 
require surgery. The future will tell about the results of ongo-
ing human fracture trials with sclerostin antibodies.
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